Inhaled corticosteroids (ICS) and risk of mycobacterium in patients with chronic respiratory diseases: A meta-analysis

Journal of Thoracic Disease

Volumn 6, Issue 7, 2014, Pages 971-978

  Ni, Songshi ^a   Fu, Zhenxue ^a   Zhao, Jing ^a   Liu, Hua ^a  

^a NANTONG UNIVERSITY   (China)

Author keywords

Inhaled corticosteroids (ICS); Meta analysis; Mycobacterium; Risk

Indexed keywords

BECLOMETASONE; BUDESONIDE; CICLESONIDE; CORTICOSTEROID DERIVATIVE; FLUNISOLIDE; FLUTICASONE; TRIAMCINOLONE;

ARTICLE; ATYPICAL MYCOBACTERIUM; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC RESPIRATORY TRACT DISEASE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG MEGADOSE; DRUG USE; HUMAN; INFECTION RISK; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; META ANALYSIS; MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS; RISK ASSESSMENT;

EID: 84905911980     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2014.07.03     Document Type: Article

References (29)

1. Mak VH, Melchor R, Spiro SG. Easy bruising as a side-effect of inhaled corticosteroids. Eur Respir J 1992;5:1068-74.
2. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and metaanalysis. Arch Intern Med 1999;159:941-55.
3. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000;343:1902-9.
4. Ernst P, Baltzan M, Deschênes J, et al. Low-dose inhaled and nasal corticosteroid use and the risk of cataracts. Eur Respir J 2006;27:1168-74.
5. Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med 1997;337:8-14.
6. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89.
7. Kardos P, Wencker M, Glaab T, et al. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:144-9.
8. Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177:19-26.
9. Ernst P, Gonzalez AV, Brassard P, et al. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007;176:162-6.
10. Jen R, Rennard SI, Sin DD. Effects of inhaled corticosteroids on airway inflammation in chronic obstructive pulmonary disease: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis 2012;7:587-95.
11. Bahçeciler NN, Nuhoglu Y, Nursoy MA, et al. Inhaled corticosteroid therapy is safe in tuberculin-positive asthmatic children. Pediatr Infect Dis J 2000;19:215-8.
12. Jick SS, Lieberman ES, Rahman MU, et al. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 2006;55:19-26.
13. Shaikh WA. Pulmonary tuberculosis in patients treated with inhaled beclomethasone. Allergy 1992;47:327-30.
14. Smeenk FW, Klinkhamer PJ, Breed W, et al. Opportunistic lung infections in patients with chronic obstructive lung disease; a side effect of inhalation corticosteroids? Ned Tijdschr Geneeskd 1996;140:94-8.
15. Shu CC, Wu HD, Yu MC, et al. Use of high-dose inhaled corticosteroids is associated with pulmonary tuberculosis in patients with chronic obstructive pulmonary disease. Medicine (Baltimore) 2010;89:53-61.
16. Brassard P, Suissa S, Kezouh A, et al. Inhaled corticosteroids and risk of tuberculosis in patients with respiratory diseases. Am J Respir Crit Care Med 2011;183:675-8.
17. Hojo M, Iikura M, Hirano S, et al. Increased risk of nontuberculous mycobacterial infection in asthmatic patients using long-term inhaled corticosteroid therapy. Respirology 2012;17:185-90.
18. Andréjak C, Nielsen R, Thomsen VØ, et al. Chronic respiratory disease, inhaled corticosteroids and risk of nontuberculous mycobacteriosis. Thorax 2013;68:256-62.
19. Kim JH, Park JS, Kim KH, et al. Inhaled corticosteroid is associated with an increased risk of TB in patients with COPD. Chest 2013;143:1018-24.
20. Lee CH, Lee MC, Shu CC, et al. Risk factors for pulmonary tuberculosis in patients with chronic obstructive airway disease in Taiwan: a nationwide cohort study. BMC Infect Dis 2013;13:194.
21. Lee CH, Kim K, Hyun MK, et al. Use of inhaled corticosteroids and the risk of tuberculosis. Thorax 2013;68:1105-13.
22. Cota GF, de Sousa MR, Fereguetti TO, et al. Efficacy of anti-leishmania therapy in visceral leishmaniasis among HIV infected patients: a systematic review with indirect comparison. PLoS Negl Trop Dis 2013;7:e2195.
23. Vangel MG, Rukhin AL. Maximum likelihood analysis for heteroscedastic one-way random effects ANOVA in interlaboratory studies. Biometrics 1999;55:129-36.
24. Assam Assam JP, Penlap Beng V, Cho-Ngwa F, et al. Mycobacterium tuberculosis is the causative agent of tuberculosis in the southern ecological zones of Cameroon, as shown by genetic analysis. BMC Infect Dis 2013;13:431.
25. Boulet LP, Bateman ED, Voves R, et al. A randomized study comparing ciclesonide and fluticasone propionate in patients with moderate persistent asthma. Respir Med 2007;101:1677-86.
26. Brassard P, Lowe AM, Bernatsky S, et al. Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada. Arthritis Rheum 2009;61:300-4.
27. Suissa S, McGhan R, Niewoehner D, et al. Inhaled corticosteroids in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007;4:535-42.
28. Barnes PJ, Adcock IM. Glucocorticoid resistance in inflammatory diseases. Lancet 2009;373:1905-17.
29. Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011;155:179-91.